6533b86ffe1ef96bd12cd4a7
RESEARCH PRODUCT
A hantavirus nucleocapsid protein segment exposed on hepatitis B virus core particles is highly immunogenic in mice when applied without adjuvants or in the presence of pre-existing anti-core antibodies.
Rainer UlrichAstrid GeldmacherIvars PetrovskisPaul PumpensDetlev H. KrügerGalina BorisovaDace Skrastinasubject
Orthohantavirusmedicine.medical_treatmentEnzyme-Linked Immunosorbent AssaySaccharomyces cerevisiaeCross Reactionsmedicine.disease_causeAntibodies ViralVirusMiceOrthohepadnavirusAdjuvants ImmunologicmedicineEscherichia coliAnimalsImmunization ScheduleHantavirusHepatitis B virusMice Inbred BALB CVaccines SyntheticGeneral VeterinaryGeneral Immunology and MicrobiologybiologyImmunogenicityPublic Health Environmental and Occupational Healthvirus diseasesNucleocapsid Proteinsbiology.organism_classificationVirologyHepatitis B Core AntigensMice Inbred C57BLInfectious DiseasesHepadnaviridaeImmunoglobulin Gbiology.proteinMolecular MedicineFemaleAntibodyCarrier ProteinsAdjuvantPlasmidsdescription
Hepatitis B virus (HBV) core particles carrying the amino-terminal 120 amino acids (aa) of the nucleocapsid (N) protein of the hantaviruses Dobrava, Hantaan or Puumala have been demonstrated to be highly immunogenic in mice when complexed with adjuvants. Here we demonstrate that even without adjuvant, these chimeric particles induced high-titered, and strongly cross-reactive N-specific antibody responses in BALB/c and C57BL/6 mice. The induced N-specific antibodies represented all IgG subclasses. Pre-existing core-specific antibodies did not abrogate the induction of an N-specific immune response by a hantavirus N insert presented on core particles. Therefore, chimeric core particles should represent promising vaccine candidates even for anti-core positive humans.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2005-06-01 | Vaccine |